-
Taxonomy & unit
-
us-gaap: GBP
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
TC BioPharm (Holdings) plc quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from 2023 to 2024.
- TC BioPharm (Holdings) plc Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2024 was -£3.43 M, a 232% decline year-over-year.
- TC BioPharm (Holdings) plc annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was -£7 M, a 131% decline from 2022.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (GBP)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)